Objective:To explore prognostic lncRNA related with fatty acid metabolism,immune response and drug sensitivity in hepatocellular carcinoma(HCC).Methods:Bioinformatics was used to obtain HCC gene data of TCGA database,most prognostic lncRNA were screened out,and prognostic model was constructed,whose accuracy was verified by ROC curve and nomogram.GO and KEGG were used for biological analysis of lncRNA.GSVA and TMB were used to analyze immune status and mutant genes of HCC patients.TIDE score was used to analyze benefit of immunotherapy in HCC patients to identify potentially effective drugs for HCC.Results:Four lncRNAs(AC074117.1,TMCC1-AS1,LINC01063,MKLN1-AS)related to fatty acid metabolism were identified.K-M curve and ROC curve confirmed that stage and risk score could evaluate prognosis of HCC patients.Nomogram confirmed accuracy of the model prediction;GO and KEGG analysis confirmed abundant biological functions of lncRNA related to fatty acid metabolism.GSVA analysis showed that plasma cells,B cells,neutrophils,NK cells and type Ⅱ-IFN response were significantly different between two risk groups.Patients with low TMB and low risk had the best prognosis.TIDE score of high-risk group was significantly higher than that of low-risk group.Five anticancer drugs more suitable for high-risk population were screened out,namely cyclopamine,rapamy-cin,Proteasome inhibitor,paclitaxel and sunitinib.Conclusion:Prediction model constructed by 4 fatty acid metabolism-related lncRNAs helps to evaluate prognosis of HCC and may provide insights for clinical application and immunotherapy of HCC patients.

Traditional surgical resection, radiotherapy, and chemotherapy still play a dominant role in the treatment of liver cancer; however, their application in liver cancer patients is often limited by the toxic and side effects, unstable efficacy, and unclear targets of chemotherapeutic drugs. Therefore, in order to improve the efficacy of drugs in the treatment of liver cancer, nanomedicine, which has been developed in the biomedical field in recent years, has attracted more and more attention. Nano-drug delivery system has been gradually applied in clinical research for its advantages of low toxicity, wide bioavailability, controllable drug release, and good stability. This article focuses on the latest research advances in nano-drug delivery system in the treatment of liver cancer.